Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has announced its participation in Canaccord Genuity's Horizons in Oncology Virtual Conference. CEO Dr. Juan Vera will join a panel discussion titled 'CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?' scheduled for April 7, 2025, from 11:00 AM to 11:50 AM ET.
The company specializes in developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. Their innovative platform features multi antigen recognizing (MAR)-T cell therapy, designed to simultaneously target multiple tumor-associated antigens. This approach has demonstrated promising clinical results in both hematologic malignancies and solid tumors.
Marker Therapeutics (Nasdaq: MRKR), un'azienda di immuno-oncologia in fase clinica, ha annunciato la sua partecipazione alla Conferenza Virtuale Horizons in Oncology di Canaccord Genuity. Il CEO Dr. Juan Vera parteciperà a una discussione di panel intitolata 'CAR-T nei Tumori Solidi e Nuovi Approcci alle Cellule T – Innovazioni in Arrivo?', programmata per il 7 aprile 2025, dalle 11:00 alle 11:50 ET.
L'azienda si specializza nello sviluppo di immunoterapie basate su cellule T di nuova generazione per il trattamento delle neoplasie ematologiche e dei tumori solidi. La loro piattaforma innovativa presenta la terapia con cellule T a riconoscimento di multi-antigeni (MAR), progettata per colpire simultaneamente più antigeni associati ai tumori. Questo approccio ha dimostrato risultati clinici promettenti sia nelle neoplasie ematologiche che nei tumori solidi.
Marker Therapeutics (Nasdaq: MRKR), una empresa de inmuno-oncología en etapa clínica, ha anunciado su participación en la Conferencia Virtual Horizons in Oncology de Canaccord Genuity. El CEO Dr. Juan Vera se unirá a un panel de discusión titulado 'CAR-T en Tumores Sólidos y Nuevos Enfoques de Células T – ¿Avances por Delante?', programado para el 7 de abril de 2025, de 11:00 AM a 11:50 AM ET.
La empresa se especializa en el desarrollo de inmunoterapias basadas en células T de nueva generación para tratar malignidades hematológicas y tumores sólidos. Su plataforma innovadora presenta la terapia con células T que reconocen múltiples antígenos (MAR), diseñada para atacar simultáneamente múltiples antígenos asociados a tumores. Este enfoque ha demostrado resultados clínicos prometedores tanto en malignidades hematológicas como en tumores sólidos.
Marker Therapeutics (Nasdaq: MRKR), 임상 단계의 면역종양학 회사가 Canaccord Genuity의 Horizons in Oncology 가상 회의에 참여한다고 발표했습니다. CEO 후안 베라 박사는 '고형 종양에서의 CAR-T 및 새로운 T세포 접근법 – 혁신이 다가오고 있는가?'라는 제목의 패널 토론에 참여할 예정이며, 이는 2025년 4월 7일 오전 11시부터 11시 50분 ET까지 진행됩니다.
회사는 혈액 악성 종양 및 고형 종양 치료를 위한 차세대 T세포 기반 면역요법 개발에 전문화되어 있습니다. 그들의 혁신적인 플랫폼은 다중 항원 인식 (MAR)-T세포 치료법을 특징으로 하며, 이는 여러 종양 관련 항원을 동시에 타겟팅하도록 설계되었습니다. 이 접근법은 혈액 악성 종양과 고형 종양 모두에서 유망한 임상 결과를 보여주었습니다.
Marker Therapeutics (Nasdaq: MRKR), une entreprise d'immuno-oncologie en phase clinique, a annoncé sa participation à la Conférence Virtuelle Horizons in Oncology de Canaccord Genuity. Le PDG Dr. Juan Vera participera à une discussion en panel intitulée 'CAR-T dans les Tumeurs Solides et Nouvelles Approches des Cellules T – Innovations à Venir?', prévue pour le 7 avril 2025, de 11h00 à 11h50 ET.
L'entreprise se spécialise dans le développement d'immunothérapies basées sur des cellules T de nouvelle génération pour traiter les malignités hématologiques et les tumeurs solides. Leur plateforme innovante présente la thérapie par cellules T reconnaissant plusieurs antigènes (MAR), conçue pour cibler simultanément plusieurs antigènes associés aux tumeurs. Cette approche a montré des résultats cliniques prometteurs tant pour les malignités hématologiques que pour les tumeurs solides.
Marker Therapeutics (Nasdaq: MRKR), ein Unternehmen für Immunonkologie in der klinischen Phase, hat seine Teilnahme an der virtuellen Konferenz Horizons in Oncology von Canaccord Genuity angekündigt. CEO Dr. Juan Vera wird an einer Podiumsdiskussion mit dem Titel 'CAR-T bei soliden Tumoren und neue T-Zell-Ansätze – Durchbrüche bevorstehend?' teilnehmen, die für den 7. April 2025, von 11:00 bis 11:50 Uhr ET geplant ist.
Das Unternehmen ist auf die Entwicklung von Immuntherapien auf Basis von T-Zellen der nächsten Generation zur Behandlung von hämatologischen Malignitäten und soliden Tumoren spezialisiert. Ihre innovative Plattform umfasst die multi-antigen-erkennende (MAR)-T-Zelltherapie, die darauf abzielt, mehrere tumorassoziierte Antigene gleichzeitig anzugreifen. Dieser Ansatz hat vielversprechende klinische Ergebnisse sowohl bei hämatologischen Malignitäten als auch bei soliden Tumoren gezeigt.
- None.
- None.
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity’s Horizons in Oncology Virtual Conference.
Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors.
Panel Participation Details:
| Event | CG Horizons in Oncology Virtual Conference |
| Panel Title | CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead? |
| Date | Monday, April 7, 2025 |
| Time | 11:00 AM – 11:50 AM ET |
Marker Therapeutics is advancing a unique multi antigen recognizing (MAR)-T cell therapy platform designed to target multiple tumor-associated antigens simultaneously, an approach that has shown promising clinical results in hematologic malignancies and solid tumors.
To join the virtual panel discussion, please contact your Canaccord Genuity conference representative.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
Media and Investor Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
FAQ
When is Marker Therapeutics (MRKR) presenting at the Canaccord Genuity Conference?
What is Marker Therapeutics' (MRKR) main therapeutic technology?
What types of diseases does MRKR's therapy target?
What panel will MRKR's CEO participate in at the Canaccord conference?
Has MRKR's therapeutic approach shown any clinical results?
